A 35-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone
| Autor: | Torsten Konrad, Carsten Nalenz, Thomas Rostock, Boris A. Hoffmann, Björn Lange, Alexandra Marx |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Polymorphic premature ventricular beats medicine.drug_class Case Report Propafenone 030204 cardiovascular system & hematology Catecholaminergic polymorphic ventricular tachycardia Ryanodine receptor 2 03 medical and health sciences 0302 clinical medicine Internal medicine Medicine Effective treatment 030212 general & internal medicine Exercise-induced syncope Beta blocker business.industry medicine.disease Blockade cardiovascular system Cardiology Antiarrhythmic effect Cardiology and Cardiovascular Medicine business Ryanodine receptor mutation medicine.drug |
| Zdroj: | HeartRhythm Case Reports |
| ISSN: | 2214-0271 |
| DOI: | 10.1016/j.hrcr.2018.04.003 |
| Popis: | Key Teaching Points • Despite proven catecholaminergic polymorphic ventricular tachycardia (CPVT) with pathogen RyR2 mutation and recurrent syncope, patients could have a favorable long-term outcome over 35 years under treatment. • Propafenone could be effective for treatment of patients with CPVT. • The beneficial effect of the monotherapy with propafenone in our patient may result from the combined antiarrhythmic effect of this drug with Na+ channel blockade and beta blocker capabilities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|